Compare Devon Energy Corp (DVN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Devon Energy Corp trades at $48.74 (market cap $52.67B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.4× Devon Energy Corp's market cap, and Devon Energy Corp pays a 2.67% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DVN | VRTX | |
|---|---|---|
Market Cap | $52.67B | $128.16B |
Volume | 5,542,360 | 806,603 |
Sector | Energy | Health |
52-Week High | $52.07 | $557.96 |
52-Week Low | $31.74 | $407.37 |
Typical Hold Time | 136 Days | 120 Days |
Enterprise Value | $63.40B | $122.29B |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.92, up 1.87% today, with a bullish technical signal from moving averages and strong analyst support. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, while maintaining solid profitability with a 16.67% net margin. Recent news highlights activist investor pressure for strategic alternatives, including a potential sale, and ongoing M&A interest in its assets.
The outlook remains positive given undervaluation versus peers (P/E 10.41), a consensus price target of $62.40 implying 27% upside, and projected revenue growth to $19.7B in 2026. Key risks include oil price volatility, execution of asset sales, and debt levels, but institutional bullishness (71.9% buy ratings) underscores confidence in the Permian-focused strategy.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
